TY - JOUR
T1 - Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)
AU - Manzano, Roberta P.A.
AU - Peyman, Gholam A.
AU - Khan, Palwasha
AU - Carvounis, Petros E.
AU - Kivilcim, Muhamet
AU - Ren, Min
AU - Lake, Jonathan C.
AU - Chévez-Barrios, Patricia
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2007/6
Y1 - 2007/6
N2 - Aim: To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularisation in rats. Methods: Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to perform chemical cauterisation on the corneas of 16 eyes from 16 male Long Evans rats. For the following 7 days, the 10 eyes in the treatment group were instilled with bevacizumab 4 mg/ml drops twice daily, whereas the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analysed to determine the area of cornea covered by neovascularisation as a percentage of the total corneal area. Results: In the bevacizumab-treated eyes, neovascularisation covered, on average, 38.2% (15.5%) (mean (SD)) of the corneal surface compared with 63.5% (5.0%) in the control group (p<0.02, Mann-Whitney U test). Conclusion: Topically administered bevacizumab (Avastin) at a concentration of 4 mg/ml limits corneal neovascularisation following chemical injury in the male Long Evans rat model.
AB - Aim: To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularisation in rats. Methods: Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to perform chemical cauterisation on the corneas of 16 eyes from 16 male Long Evans rats. For the following 7 days, the 10 eyes in the treatment group were instilled with bevacizumab 4 mg/ml drops twice daily, whereas the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analysed to determine the area of cornea covered by neovascularisation as a percentage of the total corneal area. Results: In the bevacizumab-treated eyes, neovascularisation covered, on average, 38.2% (15.5%) (mean (SD)) of the corneal surface compared with 63.5% (5.0%) in the control group (p<0.02, Mann-Whitney U test). Conclusion: Topically administered bevacizumab (Avastin) at a concentration of 4 mg/ml limits corneal neovascularisation following chemical injury in the male Long Evans rat model.
UR - http://www.scopus.com/inward/record.url?scp=34247519047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247519047&partnerID=8YFLogxK
U2 - 10.1136/bjo.2006.107912
DO - 10.1136/bjo.2006.107912
M3 - Article
C2 - 17179168
AN - SCOPUS:34247519047
SN - 0007-1161
VL - 91
SP - 804
EP - 807
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 6
ER -